Founded on the September 18th, 2017 and headquartered near Düsseldorf, Germany, Priavoid GmbH is a biopharmaceutical company focused on the development of innovative disease-modifying therapies for patients with severe neurological disorders. Priavoid’s pharmaceutical development programs are exclusively based on d-enantiomeric peptides (all-d-peptides).

The most advanced drug in our pipeline is named PRI-002. The orally available clinical stage drug candidate directly eliminates toxic amyloid-beta (Aß) oligomers for the causal treatment of Alzheimer’s disease (AD).   Oral administration resulted in significantly improved cognitive read out in three different in vivo models.

The First-in-Human phase I single ascending dose (SAD) clinical trial of PRI-002 was successfully completed recently, demonstrating favorable safety, tolerability and pharmacokinetic profiles. The phase I multiple ascending dose (MAD) clinical trial started on December 12th, 2018.

The orally available drug candidate PRI-003 has accomplished successful PoC in an in vivo disease model of Amyotrophic lateral sclerosis (ALS). Priavoid accelerates this research program towards clinical development.

PRI-004 is our drug candidate for the treatment of neuropathic pain. The program is ready to initiate clinical research.

Priavoid’s development pipeline is targeting additional orphan and non-orphan CNS disorders caused by misfolded peptides, incl. tauopathies, Huntington’s disease (HD), and Parkinson’s disease (PD).

Cookie Preference

Please select an option. You can find more information about the consequences of your choice at Help.

Select an option to continue

Your selection was saved!



To continue, you must make a cookie selection. Below is an explanation of the different options and their meaning.

  • Accept all cookies:
    All cookies such as tracking and analytics cookies.
  • Accept first-party cookies only:
    Only cookies from this website.
  • Reject all cookies:
    No cookies except for those necessary for technical reasons are set.

You can change your cookie setting here anytime: Privacy Policy. Legal Notice